Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1959 1
1964 1
1965 4
1966 2
1967 7
1968 1
1969 4
1970 3
1971 8
1972 3
1973 4
1974 2
1975 6
1976 8
1977 5
1978 7
1979 8
1980 15
1981 12
1982 7
1983 11
1984 20
1985 17
1986 16
1987 22
1988 14
1989 22
1990 16
1991 18
1992 18
1993 22
1994 37
1995 18
1996 23
1997 22
1998 18
1999 36
2000 34
2001 51
2002 38
2003 23
2004 26
2005 32
2006 34
2007 34
2008 28
2009 33
2010 49
2011 70
2012 60
2013 59
2014 59
2015 53
2016 48
2017 39
2018 45
2019 47
2020 53
2021 90
2022 70
2023 43
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

1,441 results

Results by year

Filters applied: . Clear all
Page 1
Cannabis for the Treatment of Epilepsy: an Update.
Gaston TE, Szaflarski JP. Gaston TE, et al. Curr Neurol Neurosci Rep. 2018 Sep 8;18(11):73. doi: 10.1007/s11910-018-0882-y. Curr Neurol Neurosci Rep. 2018. PMID: 30194563 Review.
Finally, we present data from both open-label expanded access programs (EAPs) and randomized placebo-controlled trials (RCTs) of a highly purified oral preparation of CBD, which was recently approved by the FDA in the treatment of epilepsy. ...
Finally, we present data from both open-label expanded access programs (EAPs) and randomized placebo-controlled trials (RCTs) of a hi …
Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial.
Kotulska K, Kwiatkowski DJ, Curatolo P, Weschke B, Riney K, Jansen F, Feucht M, Krsek P, Nabbout R, Jansen AC, Wojdan K, Sijko K, Głowacka-Walas J, Borkowska J, Sadowski K, Domańska-Pakieła D, Moavero R, Hertzberg C, Hulshof H, Scholl T, Benova B, Aronica E, de Ridder J, Lagae L, Jóźwiak S; EPISTOP Investigators. Kotulska K, et al. Ann Neurol. 2021 Feb;89(2):304-314. doi: 10.1002/ana.25956. Epub 2020 Nov 27. Ann Neurol. 2021. PMID: 33180985 Free PMC article. Clinical Trial.
At 6 sites, subjects were randomly allocated to treatment in a 1:1 ratio in a randomized controlled trial (RCT). ...At 24 months, our pooled analysis showed preventive treatment reduced the risk of clinical seizures (odds ratio [OR] = 0.21, p = 0.032), …
At 6 sites, subjects were randomly allocated to treatment in a 1:1 ratio in a randomized controlled trial (RCT). ...At …
Epilepsy: expert opinion on emerging drugs in phase 2/3 clinical trials.
Pong AW, Ross J, Tyrlikova I, Giermek AJ, Kohli MP, Khan YA, Salgado RD, Klein P. Pong AW, et al. Expert Opin Emerg Drugs. 2022 Mar;27(1):75-90. doi: 10.1080/14728214.2022.2059464. Epub 2022 Apr 1. Expert Opin Emerg Drugs. 2022. PMID: 35341431
AREAS COVERED: ASMs in phase 2a/b-3 clinical trials target cholesterol, serotonin, sigma-1 receptors, potassium channels and metabotropic glutamate receptors. ...Clinically, the current phase 2a/b-3 agents hold promise for variety of epilepsy conditions, from developmental …
AREAS COVERED: ASMs in phase 2a/b-3 clinical trials target cholesterol, serotonin, sigma-1 receptors, potassium channels and metabotr …
Delineating clinical and developmental outcomes in STXBP1-related disorders.
Xian J, Thalwitzer KM, McKee J, Sullivan KR, Brimble E, Fitch E, Toib J, Kaufman MC, deCampo D, Cunningham K, Pierce SR, Goss J, Rigby CS, Syrbe S, Boland M, Prosser B, Fitter N, Ruggiero SM, Helbig I. Xian J, et al. Brain. 2023 Dec 1;146(12):5182-5197. doi: 10.1093/brain/awad287. Brain. 2023. PMID: 38015929 Free PMC article.
However, the longitudinal epilepsy course and developmental end points, have not yet been described in detail, which is a critical prerequisite for clinical trial readiness. Here, we assessed 1281 cumulative patient-years of seizure and developmental histories in 16 …
However, the longitudinal epilepsy course and developmental end points, have not yet been described in detail, which is a critical prerequis …
The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial.
Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, O'Callaghan FJ, Verity CM, Osborne JP; United Kingdom Infantile Spasms Study. Lux AL, et al. Lancet Neurol. 2005 Nov;4(11):712-7. doi: 10.1016/S1474-4422(05)70199-X. Lancet Neurol. 2005. PMID: 16239177 Clinical Trial.
BACKGROUND: Infantile spasms is a severe infantile seizure disorder that is difficult to treat and has a high morbidity. ...We sought to assess whether early control of spasms is associated with improved developmental or epilepsy outcomes. METHODS: Infants enrolled …
BACKGROUND: Infantile spasms is a severe infantile seizure disorder that is difficult to treat and has a high morbidity. ...We …
Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial.
O'Callaghan FJ, Edwards SW, Alber FD, Hancock E, Johnson AL, Kennedy CR, Likeman M, Lux AL, Mackay M, Mallick AA, Newton RW, Nolan M, Pressler R, Rating D, Schmitt B, Verity CM, Osborne JP; participating investigators. O'Callaghan FJ, et al. Lancet Neurol. 2017 Jan;16(1):33-42. doi: 10.1016/S1474-4422(16)30294-0. Epub 2016 Nov 10. Lancet Neurol. 2017. PMID: 27838190 Free article. Clinical Trial.
We aimed to assess whether combining the treatments would be more effective than hormonal therapy alone. METHODS: In this multicentre, open-label randomised trial, 102 hospitals (Australia [three], Germany [11], New Zealand [two], Switzerland [three], and the UK [83 …
We aimed to assess whether combining the treatments would be more effective than hormonal therapy alone. METHODS: In this multicentre, open- …
Infantile spasms.
Chugani HT. Chugani HT. Curr Opin Neurol. 1995 Apr;8(2):139-44. doi: 10.1097/00019052-199504000-00010. Curr Opin Neurol. 1995. PMID: 7620588 Review.
Technological advances have increased our ability to diagnose specific brain disorders associated with infantile spasms, and have led to new therapeutic approaches. Most infantile spasms previously classified as cryptogenic have now been shown to be as …
Technological advances have increased our ability to diagnose specific brain disorders associated with infantile spasms, and h …
Vigabatrin.
Wheless JW, Ramsay RE, Collins SD. Wheless JW, et al. Neurotherapeutics. 2007 Jan;4(1):163-72. doi: 10.1016/j.nurt.2006.11.008. Neurotherapeutics. 2007. PMID: 17199033 Free PMC article. Review.
Refractory epilepsies such as infantile spasms (IS) and complex partial seizures (CPS) can have a severe negative impact on the neurological integrity and quality of life of affected patients, in addition to drastically increasing their risk of premature mortality. …
Refractory epilepsies such as infantile spasms (IS) and complex partial seizures (CPS) can have a severe negative impact on th …
Infantile Spasms-Have We Made Progress?
Kelley SA, Knupp KG. Kelley SA, et al. Curr Neurol Neurosci Rep. 2018 Apr 19;18(5):27. doi: 10.1007/s11910-018-0832-8. Curr Neurol Neurosci Rep. 2018. PMID: 29671077 Review.
PURPOSE OF THE REVIEW: The care of children with infantile spasms is full of areas of ambiguity, despite practice parameters and randomized trials. This review is to update the current care of children with infantile spasms. RECENT FINDINGS: Sev …
PURPOSE OF THE REVIEW: The care of children with infantile spasms is full of areas of ambiguity, despite practice parameters a …
Infantile spasms.
Zupanc ML. Zupanc ML. Expert Opin Pharmacother. 2003 Nov;4(11):2039-48. doi: 10.1517/14656566.4.11.2039. Expert Opin Pharmacother. 2003. PMID: 14596657 Review.
A small percentage of patients have idiopathic infantile spasms, with normal growth and development prior to the onset of infantile spasms and no known aetiology. ...Infantile spasms are resistant to most of the standard antiepileptic dru …
A small percentage of patients have idiopathic infantile spasms, with normal growth and development prior to the onset of i …
1,441 results